Atrioventricular Nodal Reentry TachycardiaMAP-AVNRTNCT07630480
3D Mapping Versus Conventional Ablation in AVNRT
A study testing Conventional Slow Pathway Ablation and 3D Electroanatomical Mapping-Guided Ablation in people with Atrioventricular Nodal Reentry Tachycardia and Supraventricular Tachycardia (SVT), run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
This prospective randomized interventional study compared conventional fluoroscopy-guided slow pathway ablation versus three-dimensional electroanatomical mapping-guided ablation in patients with electrophysiologically confirmed typical atrioventricular nodal re-entrant tachycardia (AVNRT). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrioventricular Nodal Reentry Tachycardia, Supraventricular Tachycardia (SVT)
- What is being tested?
- Conventional Slow Pathway Ablation and 3D Electroanatomical Mapping-Guided Ablation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Dec 2023to 23 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Sustained symptomatic supraventricular tachycardia with surface ECG features highly suggestive of atrioventricular nodal re-entrant tachycardia (AVNRT).
- Electrophysiologically confirmed typical (slow-fast) AVNRT during the index electrophysiology study.
- Ability to provide written informed consent.
Who cannot join
- Coexisting arrhythmia requiring concurrent catheter ablation during the same procedure.
- Non-inducible AVNRT at the time of electrophysiological study.
- Antiarrhythmic drug use within 48 hours before the procedure or ongoing amiodarone therapy.
- Hemodynamic instability precluding safe catheter manipulation.
- Pregnancy.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Kafr Elsheikh Univfersity Hospital
Kafr ash Shaykh, Kafr el-Sheikh Governorate, 11355
About this study
Official title: Three-Dimensional Electroanatomical Mapping Versus Conventional Fluoroscopy-Guided Slow Pathway Ablation for Typical Atrioventricular Nodal Re-Entrant Tachycardia: A Prospective Randomized Study
This prospective randomized interventional study compared conventional fluoroscopy-guided slow pathway ablation versus three-dimensional electroanatomical mapping-guided ablation in patients with electrophysiologically confirmed typical atrioventricular nodal re-entrant tachycardia (AVNRT). A total of 108 patients were screened for eligibility, of whom 80 eligible patients were randomized in a 1:1 ratio to either conventional fluoroscopic ablation or 3D mapping-guided ablation. Following post-randomization dropouts, the final analysis included 38 patients in the conventional group and 36 patients in the 3D mapping group. The study evaluated fluoroscopy exposure, procedural efficacy, complete slow pathway elimination, procedural success, complications, and arrhythmia recurrence during follow-up.
Read the detailed description
Atrioventricular nodal re-entrant tachycardia (AVNRT) is one of the most common forms of paroxysmal supraventricular tachycardia. Catheter ablation targeting the slow AV nodal pathway is considered definitive therapy with high procedural success rates.
Conventional fluoroscopy-guided ablation mainly relies on anatomical landmarks and intracardiac electrogram interpretation. However, fluoroscopy exposure remains an important concern for both patients and operators. Three-dimensional electroanatomical mapping systems allow detailed reconstruction of the triangle of Koch and facilitate substrate-guided ablation using voltage, activation, and fractionated electrogram mapping techniques. These systems may reduce fluoroscopy exposure and improve procedural precision and efficacy.
This prospective randomized two-arm interventional study was conducted at the Cardiology Department, Kafr El-Sheikh University Hospital, between December 2023 and November 2025. A total of 108 consecutive patients with symptomatic supraventricular tachycardia suggestive of AVNRT were screened for eligibility. Following assessment according to predefined inclusion and exclusion criteria, 80 eligible patients with electrophysiologically confirmed typical AVNRT were enrolled and randomized in a 1:1 ratio to either conventional fluoroscopy-guided slow pathway ablation (Conventional group, n = 40) or three-dimensional electroanatomical mapping-guided slow pathway ablation (3D group, n = 40).
During the study period, post-randomization dropouts and exclusions occurred in both groups. Consequently, the final analysis included 38 patients in the conventional ablation group and 36 patients in the 3D mapping-guided ablation group.
In the conventional arm, ablation was performed using standard fluoroscopic anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch. In the 3D mapping arm, high-density electroanatomical mapping using CARTO or EnSite X systems was performed with integrated voltage, activation, and fractionated electrogram mapping to identify optimal ablation targets.
Primary outcomes included fluoroscopy time, fluoroscopy dose, complete slow pathway elimination, and procedural success defined as non-inducibility of sustained AVNRT after ablation. Secondary outcomes included total procedure duration, number and duration of radiofrequency applications, complications, recurrence during follow-up, hospital stay duration, need for redo ablation, and predictors of complete slow pathway elimination.
- Being tested
- Conventional Slow Pathway Ablation, 3D Electroanatomical Mapping-Guided Ablation
- Keywords
- AVNRT, Catheter Ablation, Electrophysiology, Three-Dimensional Mapping, Electroanatomical Mapping, Fluoroscopy, Slow Pathway Ablation
- Medical subject headings
- Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Supraventricular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conventional Slow Pathway AblationProcedure or surgery
Also called Conventional Fluoroscopy-Guided Ablation
Conventional fluoroscopy-guided catheter ablation of the slow AV nodal pathway using anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch.
3D Electroanatomical Mapping-Guided AblationProcedure or surgery
Three-dimensional electroanatomical mapping-guided catheter ablation of the slow AV nodal pathway using CARTO or EnSite X systems with voltage and activation mapping guidance.
| Study group | Role | What they receive |
|---|---|---|
| Conventional Fluoroscopy-Guided Ablation | Active comparator | Patients underwent conventional fluoroscopy-guided slow pathway ablation using standard anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch. Receives: Procedure: Conventional Slow Pathway Ablation |
| 3D Electroanatomical Mapping-Guided Ablation | Experimental | Patients underwent three-dimensional electroanatomical mapping-guided slow pathway ablation using CARTO or EnSite X systems with integrated voltage, activation, and fractionated electrogram mapping. Receives: Procedure: 3D Electroanatomical Mapping-Guided Ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Fluoroscopy Radiation Dose During Catheter Ablation
Total fluoroscopy radiation dose measured during the catheter ablation procedure, reported in mGy.
Measured: At completion of the index ablation procedure
Total Fluoroscopy Exposure Time During Catheter Ablation
Total duration of fluoroscopy exposure during the catheter ablation procedure, reported in minutes.
Measured: At completion of the index ablation procedure
Secondary outcomes (2)
Number of Participants With Complete Slow Pathway Elimination
Complete abolition of slow pathway conduction and disappearance of the anterograde AH jump following catheter ablation.
Measured: At completion of the index ablation procedure
Number of Participants with Acute Procedural Success
Acute procedural success defined as non-inducibility of sustained AVNRT after catheter ablation under baseline conditions and following isoproterenol infusion.
Measured: At completion of the index ablation procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2026
- Study start30 Dec 2023
- Primary completion23 Nov 2025
- Study completion23 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrioventricular Nodal Reentry TachycardiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Eligible patients with electrophysiologically confirmed typical AVNRT were randomized in a 1:1 ratio to either conventional fluoroscopy-guided slow pathway ablation or three-dimensional electroanatomical mapping-guided ablation.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Soha Mahmoud Ali Elshibly, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07630480
- Sponsor's protocol ID
- AVNRT-3D-2025
- Acronym
- MAP-AVNRT
- Status last verified
- Jun 2026
- First submitted
- 23 May 2026
- Last updated
- 5 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data (IPD) sharing plans have not yet been finalized at the time of study registration.
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Three-Dimensional Electroanatomical Mapping Versus Conventional Fluoroscopy-Guided Slow Pathway Ablation for Typical Atrioventricular Nodal Re-Entrant Tachycardia: A Prospective Randomized Study
- ClinicalTrials.gov ID
- NCT07630480
- Acronym / sponsor ID
- MAP-AVNRT / AVNRT-3D-2025
- Keywords
- AVNRT, Catheter Ablation, Electrophysiology, Three-Dimensional Mapping, Electroanatomical Mapping, Fluoroscopy, Slow Pathway Ablation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 30 Dec 2023 (actual)
- Primary completion
- 23 Nov 2025 (actual)
- Study completion
- 23 Nov 2025 (actual)
- First posted
- 5 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective randomized interventional study compared conventional fluoroscopy-guided slow pathway ablation versus three-dimensional electroanatomical mapping-guided ablation in patients with electrophysiologically confirmed typical atrioventricular nodal re-entrant tachycardia (AVNRT). A total of 108 patients were screened for eligibility, of whom 80 eligible patients were randomized in a 1:1 ratio to either conventional fluoroscopic ablation or 3D mapping-guided ablation. Following post-randomization dropouts, the final analysis included 38 patients in the conventional group and 36 patients in the 3D mapping group. The study evaluated fluoroscopy exposure, procedural efficacy, complete slow pathway elimination, procedural success, complications, and arrhythmia recurrence during follow-up.
Detailed description
Atrioventricular nodal re-entrant tachycardia (AVNRT) is one of the most common forms of paroxysmal supraventricular tachycardia. Catheter ablation targeting the slow AV nodal pathway is considered definitive therapy with high procedural success rates.
Conventional fluoroscopy-guided ablation mainly relies on anatomical landmarks and intracardiac electrogram interpretation. However, fluoroscopy exposure remains an important concern for both patients and operators. Three-dimensional electroanatomical mapping systems allow detailed reconstruction of the triangle of Koch and facilitate substrate-guided ablation using voltage, activation, and fractionated electrogram mapping techniques. These systems may reduce fluoroscopy exposure and improve procedural precision and efficacy.
This prospective randomized two-arm interventional study was conducted at the Cardiology Department, Kafr El-Sheikh University Hospital, between December 2023 and November 2025. A total of 108 consecutive patients with symptomatic supraventricular tachycardia suggestive of AVNRT were screened for eligibility. Following assessment according to predefined inclusion and exclusion criteria, 80 eligible patients with electrophysiologically confirmed typical AVNRT were enrolled and randomized in a 1:1 ratio to either conventional fluoroscopy-guided slow pathway ablation (Conventional group, n = 40) or three-dimensional electroanatomical mapping-guided slow pathway ablation (3D group, n = 40).
During the study period, post-randomization dropouts and exclusions occurred in both groups. Consequently, the final analysis included 38 patients in the conventional ablation group and 36 patients in the 3D mapping-guided ablation group.
In the conventional arm, ablation was performed using standard fluoroscopic anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch. In the 3D mapping arm, high-density electroanatomical mapping using CARTO or EnSite X systems was performed with integrated voltage, activation, and fractionated electrogram mapping to identify optimal ablation targets.
Primary outcomes included fluoroscopy time, fluoroscopy dose, complete slow pathway elimination, and procedural success defined as non-inducibility of sustained AVNRT after ablation. Secondary outcomes included total procedure duration, number and duration of radiofrequency applications, complications, recurrence during follow-up, hospital stay duration, need for redo ablation, and predictors of complete slow pathway elimination.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Eligible patients with electrophysiologically confirmed typical AVNRT were randomized in a 1:1 ratio to either conventional fluoroscopy-guided slow pathway ablation or three-dimensional electroanatomical mapping-guided ablation.
| Arm | Type | Receives |
|---|---|---|
| Conventional Fluoroscopy-Guided Ablation | Active comparator | Procedure: Conventional Slow Pathway AblationPatients underwent conventional fluoroscopy-guided slow pathway ablation using standard anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch. |
| 3D Electroanatomical Mapping-Guided Ablation | Experimental | Procedure: 3D Electroanatomical Mapping-Guided AblationPatients underwent three-dimensional electroanatomical mapping-guided slow pathway ablation using CARTO or EnSite X systems with integrated voltage, activation, and fractionated electrogram mapping. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Sustained symptomatic supraventricular tachycardia with surface ECG features highly suggestive of atrioventricular nodal re-entrant tachycardia (AVNRT).
- Electrophysiologically confirmed typical (slow-fast) AVNRT during the index electrophysiology study.
- Ability to provide written informed consent.
Key exclusion criteria (5 listed)
- Coexisting arrhythmia requiring concurrent catheter ablation during the same procedure.
- Non-inducible AVNRT at the time of electrophysiological study.
- Antiarrhythmic drug use within 48 hours before the procedure or ongoing amiodarone therapy.
- Hemodynamic instability precluding safe catheter manipulation.
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conventional Slow Pathway AblationAlso: Conventional Fluoroscopy-Guided AblationConventional fluoroscopy-guided catheter ablation of the slow AV nodal pathway using anatomical landmarks and intracardiac electrogram criteria within the triangle of Koch. | Procedure or surgery | Conventional Fluoroscopy-Guided Ablation |
| 3D Electroanatomical Mapping-Guided AblationThree-dimensional electroanatomical mapping-guided catheter ablation of the slow AV nodal pathway using CARTO or EnSite X systems with voltage and activation mapping guidance. | Procedure or surgery | 3D Electroanatomical Mapping-Guided Ablation |
Primary outcome
Total Fluoroscopy Radiation Dose During Catheter Ablation
Time frame: At completion of the index ablation procedure
Total fluoroscopy radiation dose measured during the catheter ablation procedure, reported in mGy.
Total Fluoroscopy Exposure Time During Catheter Ablation
Time frame: At completion of the index ablation procedure
Total duration of fluoroscopy exposure during the catheter ablation procedure, reported in minutes.
2 secondary outcomes
Number of Participants With Complete Slow Pathway Elimination
Time frame: At completion of the index ablation procedure
Number of Participants with Acute Procedural Success
Time frame: At completion of the index ablation procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data (IPD) sharing plans have not yet been finalized at the time of study registration.
Related trials for Atrioventricular Nodal Reentry Tachycardia
Recruiting
Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping.
Atrioventricular Nodal Reentry Tachycardia, Supraventricular Tachycardia
Recruiting
NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia
Supraventricular Tachycardia, Paroxysmal Supraventricular Tachycardia
Not yet recruitingObservational study
Comparative Outcomes of Radiofrequency Ablation of Concealed and Manifest Accessory Pathways: a Single Center, Retrospective Observational Study
Atrioventricular Reentrant Tachycardias, Wolff-Parkinson-White (WPW) Syndrome
Not yet recruiting
Differentiate AVNRT from Orthodromic AVRT
SVT
Enrolling by invitationObservational study
Intracardiac Echocardiography Guided Slow Pathway Cryoablation
Atrioventricular Nodal Reentry Tachycardia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conventional Slow Pathway Ablation and 3D Electroanatomical Mapping-Guided Ablation in people with Atrioventricular Nodal Reentry Tachycardia and Supraventricular Tachycardia (SVT), run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Fluoroscopy Radiation Dose During Catheter Ablation (time frame: At completion of the index ablation procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026.